Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
TOIIW
Upturn stock ratingUpturn stock rating

The Oncology Institute Inc (TOIIW)

Upturn stock ratingUpturn stock rating
$0.14
Last Close (24-hour delay)
Profit since last BUY55.56%
upturn advisory
Consider higher Upturn Star rating
BUY since 22 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

08/14/2025: TOIIW (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

0 Analysts rated it

Very few follow this stock; limited insights, higher-risk early investing.

Analysis of Past Performance

Type Stock
Historic Profit -34.01%
Avg. Invested days 27
Today’s Advisory Consider higher Upturn Star rating
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 08/14/2025

Key Highlights

Company Size ETF
Market Capitalization 0 USD
Price to earnings Ratio -
1Y Target Price -
Price to earnings Ratio -
1Y Target Price -
Volume (30-day avg) -
Beta 0.16
52 Weeks Range 0.01 - 0.20
Updated Date 06/14/2025
52 Weeks Range 0.01 - 0.20
Updated Date 06/14/2025
Dividends yield (FY) -
Basic EPS (TTM) -602.09

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -15.96%
Operating Margin (TTM) -9.49%

Management Effectiveness

Return on Assets (TTM) -17.66%
Return on Equity (TTM) -277.62%

Valuation

Trailing PE -
Forward PE -
Enterprise Value -
Price to Sales(TTM) -
Enterprise Value -
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -
Shares Outstanding -
Shares Floating 66946108
Shares Outstanding -
Shares Floating 66946108
Percent Insiders -
Percent Institutions -

ai summary icon Upturn AI SWOT

The Oncology Institute Inc

stock logo

Company Overview

overview logo History and Background

The Oncology Institute, Inc. (TOI) was founded to deliver value-based community cancer care and is committed to helping make cancer care more accessible and affordable to patients.

business area logo Core Business Areas

  • Comprehensive Cancer Care: TOI operates a network of community-based cancer centers, providing a full range of cancer care services, including medical oncology, radiation oncology, and hematology.
  • Value-Based Care Programs: TOI focuses on value-based care models, aiming to improve patient outcomes and reduce healthcare costs.
  • Clinical Trials: TOI participates in clinical trials, offering patients access to cutting-edge treatments and research.

leadership logo Leadership and Structure

The leadership team includes key executives focused on clinical operations, finance, and business development. The organizational structure consists of a corporate headquarters supporting a network of community-based clinics.

Top Products and Market Share

overview logo Key Offerings

  • Medical Oncology Services: Chemotherapy, immunotherapy, targeted therapy, and other systemic treatments. Limited market share data available specifically for TOI. Competitors include large hospital systems and other oncology groups.
  • Radiation Oncology Services: Radiation therapy for various cancer types. Limited market share data available specifically for TOI. Competitors include large hospital systems and other oncology groups.
  • Hematology Services: Treatment of blood disorders and cancers. Limited market share data available specifically for TOI. Competitors include large hospital systems and other hematology groups.

Market Dynamics

industry overview logo Industry Overview

The oncology market is growing due to an aging population and advancements in cancer treatment. It is highly competitive and evolving towards value-based care models.

Positioning

TOI positions itself as a provider of comprehensive, value-based cancer care in community settings, aiming to improve accessibility and affordability.

Total Addressable Market (TAM)

The global oncology market is estimated at hundreds of billions of dollars. TOI's position allows it to capture a segment of this market focused on community-based and value-based care.

Upturn SWOT Analysis

Strengths

  • Value-based care model
  • Community-based clinics
  • Comprehensive service offerings
  • Participation in clinical trials

Weaknesses

  • Limited brand recognition compared to larger hospital systems
  • Reliance on reimbursement rates
  • Smaller scale compared to national oncology providers
  • High debt

Opportunities

  • Expansion into new geographic markets
  • Increased adoption of value-based care models
  • Partnerships with payers and healthcare systems
  • Technological advancements in cancer treatment

Threats

  • Changes in reimbursement policies
  • Increased competition from larger healthcare providers
  • Rising operating costs
  • Drug pricing pressures

Competitors and Market Share

competitor logo Key Competitors

  • USON
  • CRGV
  • HCA

Competitive Landscape

TOI faces competition from larger hospital systems and national oncology providers. Its advantage lies in its community-based model and value-based care approach. Disadvantages include smaller scale and brand recognition.

Growth Trajectory and Initiatives

Historical Growth: Historical growth can be determined by analyzing past revenue and patient volume trends from financial reports.

Future Projections: Future growth projections can be found in analyst reports and company presentations, focusing on revenue growth, clinic expansion, and patient volume.

Recent Initiatives: Recent initiatives would be related to clinic expansion, partnerships, and the development of value-based care programs.

Summary

The Oncology Institute operates under a value-based care model focused on community-based cancer care. While its unique approach offers potential, the company faces stiff competition from larger healthcare providers and relies heavily on reimbursement rates. Its small scale and high debt remain challenges. The company should focus on expanding its network, securing partnerships, and carefully managing expenses to improve its financial stability and market position.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company filings (SEC)
  • Analyst reports
  • Industry publications

Disclaimers:

This analysis is based on publicly available information and is not financial advice. Market share estimates are approximate and may vary depending on the source.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About The Oncology Institute Inc

Exchange NASDAQ
Headquaters Cerritos, CA, United States
IPO Launch date 2020-06-04
CEO & Executive Director Dr. Daniel Virnich FACHE, M.B.A., M.D.
Sector Healthcare
Industry Medical Care Facilities
Full time employees 825
Full time employees 825

The Oncology Institute, Inc., an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, counseling services, and 24/7 patient assistance services. The company also provides and manages clinical trials, palliative care programs, stem cell transplants services, other care delivery models associated with non-community-based academic, and tertiary care settings; and conducts clinical trials for a range of pharmaceutical, and medical device companies. It serves adult and senior cancer patients. The Oncology Institute, Inc. was founded in 2007 and is headquartered in Cerritos, California.